Bristol Myers Squibbvs.Merck & Co.
BMY vs MRK · both in Big pharma, part of the Medicine, pharma & life science value chain: Large, diversified pharmaceutical groups with broad portfolios across therapeutic areas.
Merck & Co. is about 2.9× larger than Bristol Myers Squibb by market cap; Bristol Myers Squibb trades at the lower P/E (13.0 vs 111.0); year to date, Merck & Co. leads (+35.3% vs +10.5%).
Side by side
| BMY | MRK | |
|---|---|---|
| Market cap | $121B | $352B |
| Price | $59.12 | $145.60 |
| Today | −0.8% | +2.3% |
| Return YTD | +10.5% | +35.3% |
| Return 1Y | +33.8% | +64.8% |
| Since June 26, 2026 | +2.8% | +13.2% |
| P/E | 13.0 | 111.0 |
| P/S | 2.5 | 5.3 |
| P/B | 5.4 | 8.4 |
Data as of 2026-10-09 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
Bristol Myers SquibbBMY
Opdivo made the company's name in oncology. Immunology and haematology fill out the portfolio, with neuroscience coming through the pipeline.
Full BMY profile →Merck & Co.MRK
Keytruda is the centre of the oncology business, which sits next to a substantial vaccines portfolio. Animal health forms a third division.
Full MRK profile →More BMY & MRK comparisons
Other head-to-heads in the Big pharma segment.